Adam Levysohn | Head of Global Market Access Biogen Biosimilars Business Unit
Biogen

Adam Levysohn, Head of Global Market Access Biogen Biosimilars Business Unit, Biogen

Adam is the global head of Biogen’s biosimilars business unit value and access team. Adam has more than 15 years of experience in value and access. Prior to Biogen, he was at Novo Nordisk in global, regional and affiliate roles including head of the company’s global market access and market access Europe. After Novo Nordisk, Adam was responsible for Ilaris (canakinumab) market access at Novartis. Before Biogen, he was the head of global market access for CardioMetabolic at Takeda Pharmaceuticals.

Appearances:



Biosimilars Day 1 - Tuesday 31st October 2017 @ 09:00

Chair’s opening remarks

Biosimilars Day 1 - Tuesday 31st October 2017 @ 09:10

'Unlocking the value of Biosimilars' - The market access perspective

  • Negotiating price and return
  • Finding a ‘go to market’ approach

Biosimilars Day 1 - Tuesday 31st October 2017 @ 09:50

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

  • Consisting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
     
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gainsharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines?

Biosimilars Day 1 - Tuesday 31st October 2017 @ 11:35

Plenary Roundtable Discussion Session

8 senior level tables hosted by thought leaders on key challenges and opportunities in antibody drug development. Participants are invited to join the group discussions on a topic of importance to them.

ROUNDTABLE 3 Pricing, reimbursement and market access

back to speakers